TY - JOUR
T1 - Genetic susceptibility to psoriasis and psoriatic arthritis
T2 - Implications for therapy
AU - Hébert, H. L.
AU - Ali, F. R.
AU - Bowes, J.
AU - Griffiths, C. E.M.
AU - Barton, A.
AU - Warren, R. B.
PY - 2012/3
Y1 - 2012/3
N2 - The era of genome-wide association studies has revolutionized the search for genetic susceptibility loci in complex genetic conditions such as psoriasis. There are currently 16 loci with confirmed evidence for association with psoriasis susceptibility but there is the potential for more to be discovered as the genetic heritability of the disease has not yet been fully explained. Many of the associated loci overlap with those for psoriatic arthritis. In contrast to psoriasis susceptibility, few studies have been performed to identify predictors of drug response in psoriasis. As large-scale collaborations and registries for psoriasis and psoriatic arthritis are established, it is likely that a genome-wide approach may be used as a more effective method of searching for genetic predictors of treatment response. However, candidate gene studies will still have a role; for example, it is likely that some disease susceptibility genes will also be markers of treatment response, based on evidence from other diseases. This review summarizes recent advances in investigating the role genetics plays in psoriasis susceptibility and contrasts these to advances made in psoriatic arthritis. Further, it describes the genetics of treatment response in the two diseases and indicates how susceptibility loci could be used to identify drug response in the future.
AB - The era of genome-wide association studies has revolutionized the search for genetic susceptibility loci in complex genetic conditions such as psoriasis. There are currently 16 loci with confirmed evidence for association with psoriasis susceptibility but there is the potential for more to be discovered as the genetic heritability of the disease has not yet been fully explained. Many of the associated loci overlap with those for psoriatic arthritis. In contrast to psoriasis susceptibility, few studies have been performed to identify predictors of drug response in psoriasis. As large-scale collaborations and registries for psoriasis and psoriatic arthritis are established, it is likely that a genome-wide approach may be used as a more effective method of searching for genetic predictors of treatment response. However, candidate gene studies will still have a role; for example, it is likely that some disease susceptibility genes will also be markers of treatment response, based on evidence from other diseases. This review summarizes recent advances in investigating the role genetics plays in psoriasis susceptibility and contrasts these to advances made in psoriatic arthritis. Further, it describes the genetics of treatment response in the two diseases and indicates how susceptibility loci could be used to identify drug response in the future.
UR - http://www.scopus.com/inward/record.url?scp=84857578523&partnerID=8YFLogxK
U2 - 10.1111/j.1365-2133.2011.10712.x
DO - 10.1111/j.1365-2133.2011.10712.x
M3 - Review article
C2 - 22050552
AN - SCOPUS:84857578523
SN - 0007-0963
VL - 166
SP - 474
EP - 482
JO - British Journal of Dermatology
JF - British Journal of Dermatology
IS - 3
ER -